Prof Jane Speight joins team of 23 international experts for a major new European study into one of the most common and serious complications of diabetes – hypoglycaemia.
HypoRESOLVE (Hypoglycaemia – Redefining SOLutions for better liVEs) is a 4-year project, launched last month at a meeting in Copenhagen. It is an international and multidisciplinary consortium of clinicians, academics, people with diabetes and industry partners to focus on improving our understanding, and reducing the burden and consequences, of hypoglycaemia (low blood glucose).
The ACBRD’s Foundation Director, Prof Jane Speight, will be co-leading the workstream focused on the psychological impact of hypoglycaemia with Prof Frans Pouwer, University of Southern Denmark, where she also holds an honorary appointment:
“Through this work, we will be conducting systematic reviews, new international qualitative studies and surveys, and a major new clinical study investigating the real-time impact of hypoglycaemia on a range of psychological outcomes. We will be training the next generation of researchers focused on understanding and reducing the psychological burden of hypoglycaemia.”
You can read more about the psychology workstream in this article published in Deakin University’s Invenio magazine. You can also read about the broader work of the HypoRESOLVE project in this media release.
Hypo-RESOLVE is supported with funding of $42 million (€26.8 million) from the Innovative Medicines Initiative (IMI), a joint undertaking of the European Commission and the European Federation of Pharmaceutical Industries and Associations (EFPIA), the JDRF, and the Leona M. and Harry B. Helmsley Charitable Trust.
HypoRESOLVE is the 100th project funded by the European Union’s Innovative Medicines Initiative (IMI), launched in its 10th anniversary year.